Measuring Information Service Outcomes: A Tale of Two Libraries

“The MISO (Measuring Information Service Outcomes) Survey is a web-based quantitative survey designed to measure how faculty, students, and staff view library and computing services in higher education” (http://www.misosurvey.org/). Fifty-five colleges will be using it in 2016 to collect user input regarding library and IT services. It has been administered at the College at Brockport every two years since 2008. SUNY Geneseo began using the tool a few years later. The survey assesses use, importance and satisfaction for a sample of campus groups that can include undergraduates, graduates, faculty and staff. The survey has helped to track changing technologies and resource use and can be used to determine service gaps (e.g., need to increase wireless coverage or improve quiet space, etc.). This poster will compare how the MISO instrument is administered and used at two public four-year comprehensive colleges in New York State. It will focus on the populations included, survey methodology, results, and how responses have been disseminated. The MISO online comparison tool will also be highlighted as a way to benchmark with peers. Suggested improvements to better use MISO data as part of assessing library impact and to ‘close the loop’ will also be included

Building Responsive Library Collections with the Getting It System Toolkit

The Getting It System Toolkit (GIST), a suite of free and open source tools & software, leverages systems to optimize library acquisitions and deselection workflow, reducing the staff time necessary to make informed decisions and process materials. The Toolkit is divided into two functions:GIST for ILLiad consists of three components that enhance the ILLiad® interlibrary loan request management software: addons, webpage customizations, and the acquisitions manager. All three components may be selectively utilized in ILLiad, for instance, ILLiad web pages may be applied to enhance the end-user request interface to add full-text discovery, or an ILLiad Addon can help ILL’s purchase on demand program discover the best way to purchase items difficult to borrow. By combining all three and customizing these components for your library, you achieve significant benefits and optimize the combination of Acquisitions and ILL services.The GIST Gift & Deselection Manager (GDM) is designed to manage and streamline library workflow for processing gifts and evaluating materials for weeding. It is standalone open-source software that automates the gathering of data for evaluating donations; including holdings, edition comparisons, full-text, and other data. The GDM also enables collection managers to perform item-by-item deselection or use the batch analysis tool to create custom deselection reports for large weeding projects.Building Responsive Library Collections with the Getting It System Toolkit combines helpful how-tos from the developers themselves, and first-hand implementation accounts from users of these time-saving tools. The volume is split into the Toolkit’s use with ILLiad and GDM, providing easy reference for users. This manual is an invaluable resource to any library using, or considering using, the Getting It System Toolkit. With contributions by: Kerri Goergen-Doll, Oregon State University Eric Joslin, Washington University in St. Louis Ryan Litsey, Texas Tech University Micquel Little, Monroe Community College, formerly at St. John Fisher College Katherine Mason, Central Michigan University, formerly at Old Dominion University Kate Ross, St. John Fisher College Susanna Van Sant, Tompkins Cortland Community Collegehttps://knightscholar.geneseo.edu/idsproject-press/1001/thumbnail.jp

Long-Term Outcomes in IgA Nephropathy

BACKGROUND: IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope and lifetime risks for kidney failure. METHODS: The IgA nephropathy cohort (2,299 adults, 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy, plus proteinuria >0.5 g/day or eGFR <60 mL/min/1.73m 2 . Incident and prevalent populations were studied as well as a population representative of a typical phase 3 clinical trial cohort. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. RESULTS: Median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. Median (95% CI) kidney survival was 11.4 (10.5, 12.5) years; mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. Based on eGFR and age at diagnosis, almost all patients are at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss ≤1 ml/min/1.73m 2 /year can be maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and "clinical trial" populations. 30% of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the "clinical trial" population each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87-0.92). CONCLUSIONS: Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being "low-risk", with proteinuria <0.88 g/g (<100 mg/mmol), have high rates of kidney failure within 10 years

How well do computer-generated faces tap face expertise?

The use of computer-generated (CG) stimuli in face processing research is proliferating due to the ease with which faces can be generated, standardised and manipulated. However there has been surprisingly little research into whether CG faces are processed in the same way as photographs of real faces. The present study assessed how well CG faces tap face identity expertise by investigating whether two indicators of face expertise are reduced for CG faces when compared to face photographs. These indicators were accuracy for identification of own-race faces and the other-race effect (ORE)-the well-established finding that own-race faces are recognised more accurately than other-race faces. In Experiment 1 Caucasian and Asian participants completed a recognition memory task for own- and other-race real and CG faces. Overall accuracy for own-race faces was dramatically reduced for CG compared to real faces and the ORE was significantly and substantially attenuated for CG faces. Experiment 2 investigated perceptual discrimination for own- and other-race real and CG faces with Caucasian and Asian participants. Here again, accuracy for own-race faces was significantly reduced for CG compared to real faces. However the ORE was not affected by format. Together these results signal that CG faces of the type tested here do not fully tap face expertise. Technological advancement may, in the future, produce CG faces that are equivalent to real photographs. Until then caution is advised when interpreting results obtained using CG faces

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials

Background: Angiotensin receptor blockers (ARBs) and β blockers are widely used in the treatment of Marfan syndrome to try to reduce the rate of progressive aortic root enlargement characteristic of this condition, but their separate and joint effects are uncertain. We aimed to determine these effects in a collaborative individual patient data meta-analysis of randomised trials of these treatments. Methods: In this meta-analysis, we identified relevant trials of patients with Marfan syndrome by systematically searching MEDLINE, Embase, and CENTRAL from database inception to Nov 2, 2021. Trials were eligible if they involved a randomised comparison of an ARB versus control or an ARB versus β blocker. We used individual patient data from patients with no prior aortic surgery to estimate the effects of: ARB versus control (placebo or open control); ARB versus β blocker; and indirectly, β blocker versus control. The primary endpoint was the annual rate of change of body surface area-adjusted aortic root dimension Z score, measured at the sinuses of Valsalva. Findings: We identified ten potentially eligible trials including 1836 patients from our search, from which seven trials and 1442 patients were eligible for inclusion in our main analyses. Four trials involving 676 eligible participants compared ARB with control. During a median follow-up of 3 years, allocation to ARB approximately halved the annual rate of change in the aortic root Z score (mean annual increase 0·07 [SE 0·02] ARB vs 0·13 [SE 0·02] control; absolute difference –0·07 [95% CI –0·12 to –0·01]; p=0·012). Prespecified secondary subgroup analyses showed that the effects of ARB were particularly large in those with pathogenic variants in fibrillin-1, compared with those without such variants (heterogeneity p=0·0050), and there was no evidence to suggest that the effect of ARB varied with β-blocker use (heterogeneity p=0·54). Three trials involving 766 eligible participants compared ARBs with β blockers. During a median follow-up of 3 years, the annual change in the aortic root Z score was similar in the two groups (annual increase –0·08 [SE 0·03] in ARB groups vs –0·11 [SE 0·02] in β-blocker groups; absolute difference 0·03 [95% CI –0·05 to 0·10]; p=0·48). Thus, indirectly, the difference in the annual change in the aortic root Z score between β blockers and control was –0·09 (95% CI –0·18 to 0·00; p=0·042). Interpretation In people with Marfan syndrome and no previous aortic surgery, ARBs reduced the rate of increase of the aortic root Z score by about one half, including among those taking a β blocker. The effects of β blockers were similar to those of ARBs. Assuming additivity, combination therapy with both ARBs and β blockers from the time of diagnosis would provide even greater reductions in the rate of aortic enlargement than either treatment alone, which, if maintained over a number of years, would be expected to lead to a delay in the need for aortic surgery. Funding: Marfan Foundation, the Oxford British Heart Foundation Centre for Research Excellence, and the UK Medical Research Council